-
1.发明申请COMPOSITION AND METHODS BASED ON NEUTRALIZING ANTIBODIES DELIVERED INTRANASALLY FOR ENHANCED THERAPEUTIC EFFICACY 审中-公开基于中性递送抗体的组合物和方法用于增强治疗效果公开(公告)号：US20160083456A1
公开(公告)日：2016-03-24
申请号：US14769795
申请日：2014-03-14
Applicant: CONTRAFECT CORPORATION
Inventor： Michael WITTEKIND , Adam VIGIL
CPC classification number: C07K16/1018 , A61K9/0043 , A61K9/007 , A61K39/42 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/543 , A61K2039/544 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/76
Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.
Abstract translation: 本发明通过直接向呼吸道施用药剂，特别是中和抗体或其活性片段，包括通过鼻内或吸入给药，提供了治疗或预防病毒，特别是流感病毒的方法。 本发明提供适用于鼻内或吸入治疗和给药的组合物。 本发明包括治疗或预防鼻内或吸入给药与腹膜内或静脉内施用抗体的方法。
-
公开(公告)号：US20210032294A1
公开(公告)日：2021-02-04
申请号：US16975321
申请日：2019-02-26
Applicant: CONTRAFECT CORPORATION
Inventor： Raymond SCHUCH , Chiara INDIANI , Michael WITTEKIND
IPC: C07K14/005 , C12N9/36 , A61P31/04
Abstract: Disclosed herein are modified lysin polypeptides thereof comprising at least one amino acid substitution as compared to a wild-type PlySs2 lysin polypeptide having an amino acid sequence of SEQ ID NO: 1, wherein the at least one amino acid substitution is in the CHAP domain and/or the SH3b domain, and wherein the modified lysin polypeptide or fragment thereof inhibits the growth, tin reduces the population, or kills at least one species of Gram-positive bacteria. Further disclosed herein are compositions comprising the modified lysin polypeptides, as well as vectors comprising a nucleic acid molecule that encodes the modified lysin polypeptide. Also disclosed herein are methods of inhibiting the growth, reducing the population, or killing at least one species of Gram-positive bacteria, methods of treating a bacterial infection, and methods of augmenting the efficacy of an antibiotic or reducing the development of antibiotic resistance.
-
3.发明申请公开(公告)号：US20170334974A1
公开(公告)日：2017-11-23
申请号：US15663021
申请日：2017-07-28
Applicant: ContraFect Corporation
Inventor： Michael WITTEKIND , Adam VIGIL
CPC classification number: C07K16/1018 , A61K9/0043 , A61K9/007 , A61K39/42 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/543 , A61K2039/544 , A61K2039/545 , C07K2317/21 , C07K2317/24 , C07K2317/33 , C07K2317/52 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/76
Abstract: The present invention provides methods for treatment or prophylaxis of viruses, particularly influenza virus, by administration of agents, particularly neutralizing antibodies or active fragments thereof, directly to the respiratory tract, including by intranasal or inhalation administration. The invention provides compositions suitable for intranasal or inhalation treatment and administration. The invention includes methods for treatment or prophylaxis combining intranasal or inhalation administration with intraperitoneal or intravenous administration of antibodies.
-
公开(公告)号：US20210008175A1
公开(公告)日：2021-01-14
申请号：US17033195
申请日：2020-09-25
Applicant: ContraFect Corporation
Inventor： Raymond SCHUCH , Robert C. NOWINSKI , Michael WITTEKIND , Han LEE , Brent SCHNEIDER
IPC: A61K38/46 , C12N9/50 , A61K31/4188 , A61K31/5377 , A61K38/12 , A61K38/47 , A61K45/06 , A61K38/14
Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
-
公开(公告)号：US20190290672A1
公开(公告)日：2019-09-26
申请号：US15760416
申请日：2016-09-16
Applicant: ContraFect Corporation
Inventor： Michael WITTEKIND , Raymond SCHUCH
IPC: A61K31/7036 , A61K38/12 , A61K38/46 , A61P31/04 , A61K9/00
Abstract: The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.
-
Patent Agency Ranking
公开(公告)号：US20230277617A1
公开(公告)日：2023-09-07
申请号：US18054587
申请日：2022-11-11
Applicant: ContraFect Corporation
Inventor： Raymond SCHUCH , Robert C. NOWINSKI , Michael WITTEKIND , Babar KHAN , Jimmy ROTOLO
CPC classification number: A61K38/16 , C12N9/503 , A01N63/50 , A61K38/164 , A61L29/08 , A61L29/16 , C07K14/315 , A61K38/47 , A61K45/06 , C12Y302/01017 , A61L2300/404 , A61L2300/406 , A61L2420/00
Abstract: The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphylococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provides compositions and methods for use in treatment or modulation of bacterial biofilm(s) and biofilm formation.
-
公开(公告)号：US20230050560A1
公开(公告)日：2023-02-16
申请号：US17811325
申请日：2022-07-08
Applicant: CONTRAFECT CORPORATION
Inventor： Raymond SCHUCH , Simon HOFFENBERG , Michael WITTEKIND
IPC: A61K38/47 , A61K38/12 , A61K45/06 , A61K9/00 , A61K31/7036 , A61K38/46 , A61K38/16 , A61P31/04 , C12N9/36
Abstract: The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.
-
公开(公告)号：US20220362352A1
公开(公告)日：2022-11-17
申请号：US17749252
申请日：2022-05-20
Applicant: CONTRAFECT CORPORATION
Inventor： Michael WITTEKIND , Raymond SCHUCH
IPC: A61K38/47 , A61K38/12 , A61K45/06 , A61K9/00 , A61K31/7036 , A61K38/46 , A61K38/16 , A61P31/04 , C12N9/36
Abstract: The present disclosure relates to methods for restoring or augmenting bactericidal activity of an antibiotic in an organ or tissue in which pulmonary surfactant is present. More specifically, the present disclosure describes that inhibition of antibiotics due to environmental factors, such as the presence of pulmonary surfactant in an organ or tissue such as the respiratory epithelium can be sidestepped or overcome and the effectiveness of the antibiotic in that milieu restored or augmented by co-administration of an antibiotic and a lysin.
-
公开(公告)号：US20210128696A1
公开(公告)日：2021-05-06
申请号：US17141692
申请日：2021-01-05
Applicant: ContraFect Corporation
Inventor： Raymond SCHUCH , Robert C. NOWINSKI , Michael WITTEKIND , Han LEE , Brent SCHNEIDER
IPC: A61K38/46 , C12N9/50 , A61K31/4188 , A61K31/5377 , A61K38/12 , A61K38/47 , A61K45/06 , A61K38/14
Abstract: The present invention provides compositions and methods for prevention, amelioration and treatment of gram positive bacteria, particularly Staphylococcal bacteria, with combinations of lysin, particularly Streptococcal lysin, particularly the lysin PlySs2, and one or more antibiotic, including daptomycin, vancomycin, oxacillin, linezolid, or related antibiotic(s).
-
公开(公告)号：US20200376096A1
公开(公告)日：2020-12-03
申请号：US16924681
申请日：2020-07-09
Applicant: CONTRAFECT CORPORATION
Inventor： Raymond SCHUCH , Simon HOFFENBERG , Michael WITTEKIND
IPC: A61K38/47 , A61K38/12 , A61K45/06 , A61K9/00 , A61K31/7036 , A61K38/46 , A61K38/16 , A61P31/04 , C12N9/36
Abstract: The present disclosure provides methods and compositions useful for the prophylactic and therapeutic amelioration and treatment of infections caused by Gram-negative bacteria, including Pseudomonas aeruginosa. The disclosure further provides compositions and methods of incorporating and utilizing lysin polypeptides of the present disclosure for augmenting the efficacy of antibiotics generally suitable for the treatment of Gram-negative bacterial infection.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.019 seconds)
